Korsana Biosciences, Inc. (KRSA)
Nasdaq · Healthcare · Biotechnology
$30.72+0.75%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.4B
- 52-week range
- $7.19 – $59.36
- 52-week change
- +70.81%
- EPS (trailing)
- −$7.07
- Analyst rating
- 1.0 Strong buy
Fiscal year to Dec 2025
- Revenue
- $2.1M (+3.70%)
- Net income
- −$3.5M
- Operating margin
- −239.8%
- Diluted EPS
- −$1.11
From the company’s annual report on SEC EDGAR.
About Korsana Biosciences, Inc.
Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system. The company advances a pipeline of THETA-enabled therapeutics with an initial focus on neurodegenerative disorders. Its lead product candidate is KRSA-028, an anti-amyloid beta antibody for the treatment of Alzheimer's disease, which combines the THETA platform with elements of anti-amyloid beta approaches and targets a clinically relevant form of amyloid beta designed to improve brain uptake while reducing effects on reticulocytes. The company is also advancing a pipeline of additional THETA-enabled therapies for other neurodegenerative diseases. Korsana Biosciences, Inc. was incorporated in 2024 and is based in Waltham, Massachusetts.
Headquarters: Waltham, United States · 19 employees · korsana.com